189 related articles for article (PubMed ID: 17699865)
1. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
[TBL] [Abstract][Full Text] [Related]
2. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
Kratz F; Ehling G; Kauffmann HM; Unger C
Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
[TBL] [Abstract][Full Text] [Related]
3. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.
Kratz F
Expert Opin Investig Drugs; 2007 Jun; 16(6):855-66. PubMed ID: 17501697
[TBL] [Abstract][Full Text] [Related]
4. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Kratz F; Walker UA
Int J Cancer; 2007 Feb; 120(4):927-34. PubMed ID: 17131338
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy.
Boga C; Fiume L; Baglioni M; Bertucci C; Farina C; Kratz F; Manerba M; Naldi M; Di Stefano G
Eur J Pharm Sci; 2009 Oct; 38(3):262-9. PubMed ID: 19695327
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
8. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
Fokkema E; Verweij J; van Oosterom AT; Uges DR; Spinelli R; Valota O; de Vries EG; Groen HJ
Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
[TBL] [Abstract][Full Text] [Related]
9. Aldoxorubicin for the treatment of soft tissue sarcoma.
Sachdev E; Sachdev D; Mita M
Expert Opin Investig Drugs; 2017 Oct; 26(10):1175-1179. PubMed ID: 28846045
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
Otterson GA; Villalona-Calero MA; Sharma S; Kris MG; Imondi A; Gerber M; White DA; Ratain MJ; Schiller JH; Sandler A; Kraut M; Mani S; Murren JR
Clin Cancer Res; 2007 Feb; 13(4):1246-52. PubMed ID: 17317836
[TBL] [Abstract][Full Text] [Related]
11. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC
Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939
[TBL] [Abstract][Full Text] [Related]
16. Role of mtDNA lesions in anthracycline cardiotoxicity.
Lebrecht D; Walker UA
Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
19. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
20. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
